- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04282252
The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation
The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation, a Preplanned Substudy of the CLASSIC Trial
Study Overview
Detailed Description
This study is a substudy to the larger CLASSIC-trial that aims to investigate restrictive and standard fluid therapy in treating septic shock. Adult patients with septic shock according to the Sepsis-3 criteria who have received at least 1 L of IV fluid in the 24 hours before screening will be screened. Patients who have had septic shock for more than 12 hours at the time of screening, who have life-threatening bleeding, or acute burn injury >10% of the body surface area, who are pregnant and those in whom consent cannot be obtained will be excluded. Blood samples will be drawn at T0 (during the first hour after enrolment), T1 (the first morning after inclusion) and T2 (the second morning) and T3 (at ICU discharge (within 24 hours before discharge)). The samples will be analyzed for high-sensitivity troponin T (hsTnT), pro-BNP, proAdrenomedulin (MR-proADM), Co-Peptin (AVP), endothelin-1 (ET-1), neuregulin-1 (NRG-1), growth differentiation factor-15 (GDF-15), metalloproteinases (MMPs), hyaluronan, syndecan-1, heparan sulfate, IL-6, TNFR and Ang-2.
Systolic and diastolic function parameters for the left and right heart will be collected at study enrolment (within 24 hours from inclusion) and at 2-3 and day 7-10 or at discharge using transthoracic or transesophageal echocardiography.
Baseline clinical and demographic data will be analyzed using chi-square or Fisher's exact test for categorical data, and the Wilcoxon rank-sum test for continuous data. The baseline and first follow-up measure of the concentration of a biomarker will be modelled using a mixed effect linear model with a person specific random effect and an interaction between time of follow-up measure (interval since first measurement) and treatment group, the stratification variables for the randomization: hematological or metastatic cancer (Y/N) and trial site as fixed effects. A mixed model will be used to analyze the pattern of biomarkers over time. Differences between intervention groups will be tested by the interaction of time and group in the same mixed model analyses. Additional covariates will be added to adjust for treating center, illness severity (SMS-score), cumulative fluid balance and comorbidities.
The investigators have based sample size calculations on both primary outcomes, hsTnT and hyaluronan concentrations, and estimated predicted differences and standard deviations found in previous comparable studies. The Jakobsen-Lange will be used to adjust for two outcomes where αi for each outcome is αi=0.05/((n+1)/2) = 0,033 which is an adjustment halfway between no adjustment and full Bonferroni adjustment with n being the number of co-primary outcomes and secondary outcomes respectively. For sample size calculations a power of 80 % will be used. Using a standard deviation of 40 ng/l of hsTnT this reveals a sample size of n=120 to detect a group difference of 22 ng/l. To account for drop-out and loss-to-follow-up an extra 10% will be added, 132 patients will be included equally distributed between the two groups. Using a standard deviation of 29 ng/ml of hyaluronan concentration reveals a sample size of n=225 to detect a group difference of 11,5 ng/ml. To account for drop-out and loss-of-follow-up an extra 10% will be added, 248 patients will be included equally distributed between the two groups.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sandra Jonmarker, MD
- Phone Number: +466161000
- Email: sandra.jonmarker@sll.se
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with septic shock according to the Sepsis-3 criteria who have received at least 1 L of IV fluid in the 24 hours before screening
Exclusion Criteria:
- Patients who have had septic shock for more than 12 hours at the time of screening
- Patients who have life-threatening bleeding
- Patients with acute burn injury >10% of the body surface area
- Pregnant patients
- Patients in whom consent cannot be obtained
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IV fluid restriction group
No IV fluids should be given unless one of the below occurs; in these cases, IV fluid may be given:
|
All i.v.
fluids used in an Intensive Care Unit.
|
Active Comparator: Standard care group
There will be no upper limit for the use of IV or oral/enteral fluids.
In particular: IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians.
These criteria are based on the Surviving Sepsis Campaign guideline.
IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid.
IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte imbalances.
|
All i.v.
fluids used in an Intensive Care Unit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Myocardial injury
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
To investigate if IV fluid restriction decreases myocardial injury measured as plasma highly sensitive Troponin T (hsTnT) concentrations.
|
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
Hyaluronan levels
Time Frame: First morning after enrolment (within 24 hours from enrollment)
|
To study the effect of conservative fluid management versus standard care on the glycocalyx by measuring the levels of hyaluronan.
|
First morning after enrolment (within 24 hours from enrollment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left ventricular systolic function, MAPSE
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
To assess the effect of IV conservative fluid management on left ventricular systolic function measured as difference in mitral annular plane systolic excursion measured in millimeters using echocardiography.
|
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
Difference in Syndecan-1 levels
Time Frame: First morning after enrolment (within 24 hours from enrollment)
|
To compare the difference in concentration of syndecan-1 at the first morning after enrolment (T1) in the conservative fluid management group versus standard care group, adjusted for the T0 values.
|
First morning after enrolment (within 24 hours from enrollment)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left ventricular systolic function, global longitudinal strain
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
To investigate if conservative fluid management improves left ventricular strain measured in per cent using echocardiography.
|
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
Effect of a conservative fluid management strategy on C-terminal pro-endothelin-1 (CT-proET-1) concentrations.
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
To investigate the effect of a conservative fluid management strategy on C-terminal pro-endothelin-1 (CT-proET-1) concentrations in pmol/L.
|
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
Effect of a conservative fluid management strategy on neuregulin-1 (NRG-1) concentrations.
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
To investigate the effect of a conservative fluid management on neuregulin-1 (NRG-1) concentrations in ng/ml.
|
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
Effect of a conservative fluid management strategy on mid-regional pro-adrenomedullin (MR-proADM) concentrations.
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
To investigate the effect of a conservative fluid management strategy mid-regional pro-adrenomedullin (MR-proADM) in nmol/l.
|
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
Effect of a conservative fluid management strategy on Growth differentiation factor-15 (GDF-15) concentrations.
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
To investigate the effect of a conservative fluid management strategy on concentrations of Growth differentiation factor-15 (GDF-15) in pg/ml.
|
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
|
Association between glycocalyx hyaluronan concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
|
To analyze the association between hyaluronan concentrations (ng/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
|
Day 3 after randomization
|
Association between heparan sulfate concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
|
To analyze the association between heparan sulfate concentrations (ng/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
|
Day 3 after randomization
|
Association between syndecan-1 concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
|
To analyze the association between syndecan-1 concentrations (pg/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
|
Day 3 after randomization
|
Association between Tumor Necrosis Factor Receptor concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
|
To analyze the association between Tumor Necrosis Factor Receptor concentrations (ng/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
|
Day 3 after randomization
|
Association between IL-6 concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
|
To analyze the association between IL-6 concentrations (pg/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
|
Day 3 after randomization
|
Association between Angiopoetin-2 concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
|
To analyze the association between Angiopoetin-2 concentrations (ng/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
|
Day 3 after randomization
|
Glycocalyx integrity defined by levels of heparan sulfate.
Time Frame: First morning after enrollment (within 24 hours from enrollment)
|
To compare the difference in concentration of heparan sulfate at the first morning after enrolment(T1) in the restrictive group compared with the control group, adjusted for the T0 values.
|
First morning after enrollment (within 24 hours from enrollment)
|
Glycocalyx integrity defined by levels of IL-6.
Time Frame: First morning after enrollment (within 24 hours from enrollment)
|
To compare the difference in concentration of IL-6 at the first morning after enrolment(T1) in the restrictive group compared with the control group, adjusted for the T0 values.
|
First morning after enrollment (within 24 hours from enrollment)
|
Glycocalyx integrity defined by levels of TNFR.
Time Frame: First morning after enrollment (within 24 hours from enrollment)
|
To compare the difference in concentration of TNFR at the first morning after enrolment(T1) in the restrictive group compared with the control group, adjusted for the T0 values.
|
First morning after enrollment (within 24 hours from enrollment)
|
Glycocalyx integrity defined by levels of Ang-2.
Time Frame: First morning after enrollment (within 24 hours from enrollment)
|
To compare the difference in concentration of Ang-2.
at the first morning after enrolment(T1) in the restrictive group compared with the control group, adjusted for the T0 values.
|
First morning after enrollment (within 24 hours from enrollment)
|
Left ventricular systolic function, LVEF
Time Frame: Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
|
To investigate if conservative fluid management improves left ventricular ejection fraction measured in per cent using echocardiography.
|
Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
|
Left ventricular systolic function, TDI
Time Frame: Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
|
To investigate if conservative fluid management improves left ventricular tissue doppler index measured in cm/s using echocardiography.
|
Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
|
Right ventricular systolic function, TDI
Time Frame: Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
|
To investigate if conservative fluid management improves right ventricular tissue doppler index measured in cm/s using echocardiography.
|
Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
|
Right ventricular systolic function, TAPSE
Time Frame: Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
|
To investigate if conservative fluid management improves right annular plane systolic excursion measured in mm using echocardiography.
|
Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maria Cronhjort, MD, PhD, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FRESH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Shock
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
-
Rennes University HospitalTerminated
Clinical Trials on I.V. SOLUTIONS
-
MerLion Pharmaceuticals GmbHCompleted
-
Bezmialem Vakif UniversityCompletedPostpartum HemorrhageTurkey
-
AbbVieBoehringer IngelheimCompletedPsoriasisUnited States, Germany, United Kingdom
-
Boehringer IngelheimCompleted
-
Savient PharmaceuticalsCompletedChronic Gout Refractory to Conventional TherapyUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationCompletedKidney Failure, AcuteSwitzerland, Italy
-
GC Biopharma CorpRecruitingHepatitis BKorea, Republic of
-
Bezmialem Vakif UniversityCompleted
-
Boehringer IngelheimCompleted
-
G. d'Annunzio UniversityCompletedAcute Kidney Injury | Contrast Media ReactionItaly